A phase III trial evaluating Magrolimab plus AZA vs. the physician’s choice of AZA/VEN or intensive chemotherapy in TP53-mutated ND AML (ENHANCE-2 study, NCT04778397) is ongoing. The gene discussed is TP53; the disease is acute myeloid leukemia.